Clinical Studies at The Retina Clinic London

To enter one of our Clinical Studies at The Retina Clinic London, please contact info@theretinacliniclondon.com or on 020 4548 5310.

We have several Observational and Interventional Clinical Studies going on at our clinic at any given moment in time.

All our current Clinical Studies are Industry-sponsored and therefore are at no cost to patients. Patients successfully recruited into some of our studies can even be reimbursed for travel and accommodation expenses. However, maximum amounts re-imbursed are Clinical Study-specific and patients are provided with all relevant details in writing.

All our Clinical Studies already have all necessary Ethics Committee approvals, as required on an individual basis.

Patients interested in participating from our Clinical Studies can phone our clinic to request an appointment to assess their suitability for any of the ongoing Clinical Studies. No referral is necessary. However, a clinic letter or an Optician/Optometrist email or letter stating vision in each eye and confirming the diagnosis and can sometimes save the patient an unnecessary screening visit.

Prof. Stanga is our Principal Investigator (PI), Examiner and Surgeon for all our Clinical Studies. Prof. Stanga is supported by his dedicated Retinal Research Team.

Dry Age-Related Macular Degeneration (Dry AMD) is the most common cause of severe loss of central vision and for which there is currently no approved treatment and carries a significant cost to the individual suffering from it as well as to society.

Patients with Geographic Atrophy secondary to Dry-AMD are offered the opportunity to participate in one of the 5 Clinical Studies at The Retina Clinic London.

Our CURRENTLY RECRUITING CLINICAL STUDIES in Dry AMD are as follows:

  • SCOPE
  • FOCUS
  • EXPLORE
  • HORIZON

Inclusion criteria:

Inclusion criteria Exclusion criteria
Over 18 years of age Previous intraocular injections
Dry-AMD in both eyes History of Wet-AMD in both eyes
DRY-AMD in one eye Wet-AMD in the other eye

At each visit will include a range of Ophthalmic tests to assess their visual function.

SCOPE: Genetics Analysis Study

An Observational Study to evaluate the natural progression of Dry-AMD, where no treatment or surgery is required.

Patient appointments required
6 visits over 4 years at: Day 1, week 12, week 24, week 48, week 72 and week 96.

FOCUS: Gene Therapy Surgery with Subretinal Injection

FOCUS: A non-randomised Interventional Study where all participants will receive a medium or high dose during a single retinal injection during surgery with follow up visits.

Patient participation consists of a screening period of up to 8 weeks, and a 5-year estimated total study length. The study eye (treatment or control) will be allocated randomly if both eyes are eligible.

Patient appointments required
Following the Clinical Study Screening (Visit 1) appointment where eligibility is confirmed, the single surgery will be scheduled within 8 weeks of the screening visit.

After surgery there is a follow-up visit the following day. Additional follow-up visits will follow at Week 1, (visit 3), week 5 (visit 4), week 12 (visit 5), week 25 (visit 6), week 36 (visit 7), week 48 (visit 8), week 72 (visit 9), week 96 (visit 10), week 144 (visit 11), week 192 (visit 12). After that, 4 remaining visits will be spread yearly.

Each visit will include a range of Visual Function tests.

EXPLORE: Gene Therapy Surgery with Subretinal Injection

A randomized Interventional Study comprised of; A single treatment Interventional Clinical Study Arm OR an Observational Clinical Study Arm (placebo). Those randomized to the treatment part of the Clinical Study will receive either a low or high dose. The number of follow up visits depend on which Clinical Study you are randomized too.

Patient participation consists of a screening period of up to 8 weeks, and a 48-week study period for a total of 56 weeks. The study eye (treatment or control) will be allocated randomly if both eyes are eligible.

Patient appointments required
Following the Clinical Study Screening (Visit 1) appointment where eligibility is confirmed, the patient will be randomised to either the treatment part of the Clinical Study or the untreated control. Those randomised within the treatment part of the Clinical Study will be randomised further into either low or high dose.

If the patient is randomised to the ‘treatment’ part of the Clinical Study the single surgery will be scheduled within 8 weeks of the screening visit (Visit 2)

After surgery there is a follow-up visit the following day. Additional follow-up visits will follow after week 1 (visit 3), week 5 (visit 4), week 8 (visit 5), week 12 (visit 6), week 36 (visit 8), week 48 (visit 9).

Those randomised to the untreated control part of the Clinical Study include: Day 1 (visit 1 Screening), week 12 (visit 6), week 24 (visit 7), week 36 (visit 8), week 48 (visit 9).

Each visit will include a range of Visual Function tests.

HORIZON: Gene Therapy Surgery with Subretinal Injection

A randomized Interventional Study comprised of; A single treatment Interventional Clinical Study Arm OR an Observational Clinical Study Arm (placebo). Those randomized to the treatment part of the Clinical Study will receive either a medium or high dose. The number of follow up visits depend on which Clinical Study you are randomized too.

Subject participation consists of a screening period of up to 8 weeks, and a 48-week study period for a total of 56 weeks. The study eye (treatment or control) will be allocated randomly if both eyes are eligible.

Patient appointments required
Following the Clinical Study Screening (Visit 1) appointment where eligibility is confirmed, the patient will be randomised to either the treatment part of the Clinical Study or the untreated control. Those randomised within the treatment part of the Clinical Study will be randomised further into either medium or high dose.

If the patient is randomised to the ‘treatment’ part of the Clinical Study the single surgery will be scheduled within 8 weeks of the screening visit (Visit 2)

After surgery there is a follow-up visit the following day. Additional follow-up visits will follow after week 1 (visit 3), week 5 (visit 4), week 8 (visit 5), week 12 (visit 6), week 36 (visit 8), week 48 (visit 9).

Each visit will include a range of Visual Function tests.

Those randomised to the untreated control part of the Clinical Study include: Day 1 (visit 1 Screening), week 12 (visit 6), week 24 (visit 7), week 36 (visit 8), week 48 (visit 9).

Each visit will include a range of Visual Function tests.

To enter one of our Clinical Studies at The Retina Clinic London, please contact info@theretinacliniclondon.com or on 020 4548 5310.